Medivir AB of Sweden expects to start a Phase 2 study early next year of a new combination treatment for hepatitis C, as part of its ongoing efforts to build a franchise around its protease inhibitor, simeprevir (TMC435). ---Subscribe to MedNous to access this article--- Clinical Research Company News
